Genomic signatures in plasma circulating tumor DNA reveal treatment response and prognostic insights in mantel cell lymphoma
This study identified plasma ctDNA as a promising biomarker that noninvasively captures tumor-derived genetic variants associated with treatment response and survival outcomes in MCL, highlighting the clinical value of ctDNA for diagnosis, recurrence prediction, and surveillance monitoring.
Authors
- Song Wang (ORCID: https://orcid.org/0000-0002-9302-8410)
- Yizi He
- Zhou Ouyang (ORCID: https://orcid.org/0009-0004-3642-016X)
- Qiuxiang Ou (ORCID: https://orcid.org/0000-0002-2961-2057)
- Hui Zhou (ORCID: https://orcid.org/0000-0001-9909-5051)
- Hua Bao (ORCID: https://orcid.org/0000-0001-5774-8755)
- Xia Chen (ORCID: https://orcid.org/0000-0003-2177-7591)
- Ling Xiao (ORCID: https://orcid.org/0000-0003-0893-1777)
- Caiqin Wang
- Xiaoying Wu (ORCID: https://orcid.org/0000-0002-7913-118X)
- Yajun Li (ORCID: https://orcid.org/0000-0002-2728-3237)
- Wei Yang (ORCID: https://orcid.org/0000-0003-3351-7076)
- Ruolan Zeng
Institutions
- Central South University (CN)
- Hunan Cancer Hospital (CN)
Publication Details
- Journal
- Cancer Cell International
- Published
- 2025-05-03
- DOI
- https://doi.org/10.1186/s12935-025-03789-9
- Citations
- 1
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province